Cessatech announces last participant dosed in pivotal trial 0205 with lead candidate CT001

Contributed by: PR Newswire

Tags

CESSATECH

More Like This

Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001

Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting

PR Newswire associated0

AmacaThera Announces Phase 1 Results of First-in-Human Study with AMT-143, Exceeding Expectations and Paving the Way for a Novel Approach to Post-Operative Pain Relief

Figure 1: Mean NPRS Over Time in Phase 3 Study of Acute Pain Following Abdominoplasty (Graphic: Business Wire)

Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain

PR Newswire associated0

AmacaThera doses First In Human Study to Evaluate, AMT-143, for Non-opioid Treatment of Post-operative Pain

PR Newswire associated0

Tetra Pharm Technologies introduces pain relieving drug in the United Kingdom

Sapient Therapeutics Announces Positive Phase 1 Results in Part B of Its Solid Dose Prescription CBD Study

Curatis on track: submission of orphan drug designation application in the US for lead product candidate